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Translational Science
Metabolic Imaging Detects Low Levels of
Glycolytic Activity That Vary with Levels of
c-Myc Expression in Patient-Derived Xenograft
Models of Glioblastoma
Richard Mair1,2,3, Alan J.Wright1,3, Susana Ros1,3, De-en Hu1,3, Tom Booth1,3,
Felix Kreis1,3, Jyotsna Rao1, Colin Watts2,3, and Kevin M. Brindle1,3,4
Abstract
13C MRI of hyperpolarized [1-13C]pyruvate metabolism
has been used in oncology to detect disease, investigate
disease progression, and monitor response to treatment with
a view to guiding treatment in individual patients. This
technique has translated to the clinic with initial studies in
prostate cancer. Here, we use the technique to investigate its
potential uses in patients with glioblastoma (GB). We
assessed the metabolism of hyperpolarized [1-13C]pyruvate
in an orthotopically implanted cell line model (U87) of GB
and in patient-derived tumors, where these were produced
by orthotopic implantation of cells derived from different
patients. Lactate labeling was higher in the U87 tumor when
compared with patient-derived tumors, which displayed
intertumoral heterogeneity, reﬂecting the intra- and inter-
tumoral heterogeneity in the patients' tumors from which
they were derived. Labeling in some patient-derived tumors
could be observed before their appearance in morphologic
images, whereas in other tumors it was not signiﬁcantly
greater than the surrounding brain. Increased lactate labeling
in tumors correlated with c-Myc–driven expression of hexo-
kinase 2, lactate dehydrogenase A, and the monocarboxylate
transporters and was accompanied by increased radioresis-
tance. Because c-Myc expression correlates with glioma
grade, this study demonstrates that imaging with hyperpo-
larized [1-13C]pyruvate could be used clinically with patients
with GB to determine disease prognosis, to detect early
responses to drugs that modulate c-Myc expression, and to
select tumors, and regions of tumors for increased radio-
therapy dose.
Signiﬁcance: Metabolic imaging with hyperpolarized
[1-13C]pyruvate detects low levels of c-Myc–driven glyco-
lysis in patient-derived glioblastoma models, which, when
translated to the clinic, could be used to detect occult
disease, determine disease prognosis, and target radiother-
apy. Cancer Res; 78(18); 5408–18. 2018 AACR.
Introduction
Gliomas represent 80% of primary tumors affecting the
adult human central nervous system and are classiﬁed into
four types. The most aggressive, grade 4 glioblastoma (GB),
accounts for more than 50% of all diagnosed adult gliomas
(1, 2). Debulking surgery followed by radiotherapy with con-
comitant administration of temozolomide is the current
standard of care treatment (3); however, median survival is
only 15 months (4). The tumor is driven by multiple genetic
alterations, including loss of the PTEN gene, ampliﬁcation of
EGFR, and increased signaling via the PI3K/Akt pathway (2, 5).
The latter pathway is activated in more than 88% of cases,
which results in upregulated glucose transporter expression
and increased glycolysis and is associated with tumor progres-
sion and resistance to treatment (6, 7). Expression of the
transcription factor c-Myc is correlated with glioma grade, and
between 60% and 80% of GB exhibit elevated levels of
Myc (8, 9). Myc also drives increased expression of the glyco-
lytic enzymes to meet the elevated biosynthetic demands of
increased cell proliferation (10).
Hyperpolarization of 13C-labeled metabolites, which can
increase their sensitivity to magnetic resonance detection by
more than 10,000 (11), has revolutionized our capability to
image metabolism in vivo (12) and has already translated to
the clinic (13). Previous 13C magnetic resonance spectroscopic
imaging studies of hyperpolarized [1-13C]pyruvate metabo-
lism in orthotopically implanted cell line models of GB have
shown much higher levels of labeled lactate in the tumor
when compared with surrounding normal brain tissue (14).
The purpose of this study was to determine whether this was
also the case in patient-derived orthotopically implanted
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xenograft (PDOX) models of GB, which more faithfully repro-
duce the biology of patient tumors than the cell line models
(15, 16), and to determine whether there were differences in
pyruvatemetabolismbetweenPDOXmodels derived fromdifferent
patients.
Materials and Methods
Assessment of intratumoral heterogeneity in patient tumors
by ﬂuorescence-guided multiregion sampling
Intraoperative sampling of 4 patients with conﬁrmed GB
was performed by an experienced neurosurgeon (C. Watts).
Cytoreductive surgery was guided by giving the patients
5-aminolevulinic acid (5-ALA) 6 hours prior to surgery (17).
Tissue sampling was performed using a Zeiss OPMI Pentero
operating microscope (Zeiss) for ﬂuorescence detection of
protoporphyrin IX (a 5-ALA metabolite; ref. 18). Written
informed consent was obtained from the patients; the studies
were conducted in accordance with the Declaration of Helsinki,
and were approved by an Institutional Review Board.
Cell culture
Brain tumor tissue was collected from patients with GB using
protocols compliant with the UK Human Tissue Act 2004 (HTA
licence ref. 12315), approved by the Local Regional Ethics Com-
mittee (LREC ref. 04/Q0108/60) and in accordance with the
Declaration ofHelsinki. Informed consent was obtained from each
patient. Tumor tissuewas disaggregated in PBS and cells isolated by
ﬁltration through a 40-mm ﬁlter (Falcon) and washed with 10 mL
red blood cell lysis buffer (Abcam). Cell viability was assessed by
Trypan blue dye exclusion and viable cells were seeded at 15,000
cells cm2 and grown as monolayer cultures on extracellular matrix
(ECM)-coated T75 ﬂasks (Engelbreth-Holm-Swarm murine sarco-
ma ECM gel–1:10 dilution, Sigma-Aldrich) in phenol red-free
Neurobasal A (Gibco)medium containing 20mmol/L L-glutamine
(Sigma-Aldrich), 1% streptomycin/penicillin/amphotericin B
(Invitrogen), 20 ng/mL hEGF (Sigma-Aldrich), 20 ng/mL hFGF
(R&D Systems), 2% B-27 (Invitrogen), and 1% N-2 (Invitrogen).
U87 cells (ATCC) were grown in DMEM supplemented with
2 mmol/L L-glutamine and 10% FBS (Gibco). Cell line authenti-
cation was performed using STR genotyping contemporaneously
with theexperiments.Cellswereusedwithin threepassagesofbeing
thawed. Mycoplasma testing was performed using RNA-capture
ELISA.
Generation of cell lines expressing doxycycline-inducible
shRNA targeting c-Myc
Short hairpin (sh)RNA sequences targeting c-MYC were cloned
into the doxycycline-inducible TetOnPLKO lentiviral vector
(Addgene; refs. 19, 20) using the following oligonucleotides:
shMYC seq F:
50-CCGGCCTGAGACAGATCAGCAACAACTCGAGTTGT-
TGCTGATCTGTCTCAGGTTTTTG
shMYC seq R:
50-AATTCAAAAACCTGAGACAGATCAGCAACAACTCG-
AGTTGTTGCTGATCTGTCTCAGG
The control sequences were:
shCtrl F:
50-CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAG-
GGCGACTTAACCTTAGG
shCtrl R:
50-AATTCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGG-
GCGACTTAACCTTAGG
Lentiviruses were produced by cotransfecting HEK 293T
cells with the shRNA plasmid and the packaging plasmids
pCMVDR8.91 (gag-pol) and pMD.G (VSV-G glycoprotein;
ref. 21). Supernatants containing lentiviruses were collected
72 hours after transfection, mixed with polybrene (8 mg/mL),
and used to infect GB4 cells. Fresh medium containing puro-
mycin (2 mg/mL) was added after 24 hours and cells were selected
for at least 48 hours.
c-Myc knockdown
Transduced GB4 cells were grown in 6-well plates to approx-
imately 50% conﬂuency in serum-free medium. Cells were then
incubatedwithdoxycycline (10ng/mL) for 48hours in serum-free
medium, harvested, and protein extracted for Western blot anal-
ysis to conﬁrm knockdown of c-Myc and determine the concen-
trations of LDHA and hexokinase 2 (HK2).
Orthotopic tumor model
Procedures were performed in compliance with project and
personal licenses issued under the United Kingdom Animals
(Scientiﬁc Procedures) Act, 1986 and were approved by the
Cancer Research UK, Cambridge Institute Animal Welfare and
Ethical Review Body. Tumors were created by intracranial implan-
tation of cells in 6-week-old (200–250g) female rnu/rnu athymic
nude rats (Charles River Laboratories; Harlan). Cells, below
passage 20, were counted and assessed for viability (Vi-CELL XR,
Beckman Coulter) before resuspension in culture media at 2 
106 cells/mL. Animals were anesthetized by inhalation of 1% to
2% isoﬂurane (Isoﬂo, Abbotts Laboratories Ltd.) in O2 (ﬂow rate
2 L/min). Analgesia, administered subcutaneously (Vetergesic,
Alstoe), contained 0.3 mg/mL buprenorphine hydrochloride and
0.135% w/v chlorocresol diluted 1:10 in 0.9% sodium chloride,
and 1 mL/kg of subcutaneous Rimadyl LA (Pﬁzer) containing
carpofen (Zoetis; 5mg/kg diluted 1: 10 in 0.9% sodium chloride).
Animals were placed in a stereotactic surgical frame (Kopf) and a
1-mmhole drilled 2mm anterior and 3mm lateral to the bregma
(right side). Five microliters of the cell suspension was delivered
6mm intracranially via a 23-gauge full displacement syringe (SGE
Analytical Science).
MRI
MR experiments were performed using a 7T spectrometer
(Agilent). Animals were anesthetized following inhalation of
1% to 2% isoﬂurane in O2 (ﬂow rate 2 L/min) and the core body
temperature, breathing, and heart rate weremonitored (SA instru-
ments Inc.). Axial 1H MR (T2-weighted) images were acquired
using a 72-mm inner-diameter 1H quadrature birdcage coil
(RAPID Biomedical GMBH) and a fast spin-echo pulse sequence
[TR, 1,500ms; TE, 40ms across amatrix of 256 256 data points
with a ﬁeld of view (FOV) of 40 40mmand 4–8 averages]. Slice
thickness was 2 mm and 15 contiguous slices were obtained.
Contrast agent-enhanced imageswere acquired using a T1-weight-
ed spoiled-gradient-echo sequence prior to and then 90 seconds
after injection of 100 mmol/kg Dotarem (Guebert). Images con-
sisted of 5 slices 1.5 mm thick with gaps of 0.3 mm centered on
the tumor with TR 43 ms, TE 4.6 ms, 27 ﬂip angle, and four
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averages. The ﬁeld of view was 40 mm  40 mm with a 256 
128 data matrix.
Proton magnetic resonance spectroscopy
Lactate spectra were acquired from single 4  4  4 mm
voxels using LASER acquisition (22) and VAPOR water
suppression (23) pulse sequences and the 72 mm diameter
volume coil for transmit and a quadrature coil placed over
the rat's head for receive (Rapid Biomedical). Spectra were
acquired with echo times (TE) of 37 and 144 ms and 512 aver-
ages, or 1,024 averages for the longer TE. In one tumor, an extra
spectrum was acquired with TE 288 ms and 1,024 averages.
Water reference spectra were acquired at a TE of 37 ms and
using 16 averages. Spectral regions between 1 and 1.6 ppm were
least-squares ﬁtted to a model of a lactate–methyl resonance
doublet, at all three echo times, and a broad lipid methylene
resonance at TE ¼ 37 ms. This ﬁtting was also used to calculate
the lactate–methyl resonance T2. The water T2 was measured
using STEAM localization, using 16 TE values between 0.005
and 0.50 seconds and 16 averages. The lactate–methyl and
water T2s were used to estimate their respective intensities at
TE ¼ 0. Assuming a tissue water concentration of 46 mol/L
(24), these intensities were used to estimate a lactate concen-
tration. Similar water and lactate spectra were acquired from
6 8 4mm voxels in normal brain; 512 averages at TE¼ 37ms
and 1,024 at TE ¼ 144 s for the lactate spectra and 16 averages at
TE¼ 37ms for the water spectra. The same T2 value for lactate and
a mean value for the water T2 in the tumors were used
for concentration calculations. Data were processed in MATLAB
(Mathworks).
Dynamic nuclear hyperpolarization
[1-13C]pyruvic acid (82 mg) containing 15 mmol/L trityl
radical, tris[8-carboxy2,2,6,6-tetra-(hydroxyethyl)-benzo-
(1,2-4,50)-bis-(1,3)-dithiole-4-yl]-methyl sodium salt (OXO63;
both GE Healthcare) was mixed with 1.5 mmol/L of gado-
terate meglumine (Guerbet) and polarized as described
previously (25). After dissolution, this gave a 184 mmol/L
hyperpolarized [1-13C]pyruvate solution at room tempe-
rature with a pH of 7.2 and between 17% and 21%
polarization.
13C magnetic resonance spectroscopic imaging
13C spectroscopic images were acquired using a 20-mm
diameter transmit/receive surface coil (Varian) inside the
72-mm diameter 1H volume coil and positioned under the
supine rat head. T2-weighted
1H images were used to deﬁne a
6-mm slice that incorporated the maximum dimensions of the
tumor. A slice-selective shim was then performed. Hyperpo-
larized [1-13C]pyruvate (10 mL/kg) was injected via a tail vein
cannula, which took approximately 10 seconds. Single time
point axial 13C chemical shift images were obtained from the
6-mm slice, where image acquisition started 20 seconds after
pyruvate injection (TR 30 ms; TE 1.2 ms; FOV 40  40 mm;
data matrix 32  32; sinc excitation pulse with approximate 5
ﬂip angle at 13 mm from the surface coil; spectral width 6,010
Hz; acquisition time 21.3 ms; 128 complex data point pairs;
with phase-encoding gradients preceding signal acquisition).
Lactate-to-pyruvate ratios were calculated using an in-house
MATLAB script. Voxels were included if the signal was 3.5
times the SD determined from 100 voxels in noise regions,
and if there was an adjacent voxel that met this criterion. Areas
under the peaks were calculated by time-domain ﬁtting of
the resonances after spatial Fourier transformation. Animals
implanted with GB4 c-myc KD cells were imaged when tumors
were >0.1 cm3. They were then fed a doxycycline diet for
1 week and reimaged (doxycycline diet, 0.2 g/kg food pellet,
Harlan D.98186).
Determination of sensitivity to radiotherapy
GB1 and GB4 cell lines were grown in duplicate to 50%
conﬂuence and then treated with a single dose (15 Gy) of
radiotherapy using a Cs-137 irradiator (IBL 637; CIS Bio Inter-
national). Cell viability was determined using an automated
Trypan blue dye exclusion assay (ViCell) at 1, 3, 5, and 7 days
after irradiation.
GB4 control cells, which included nontransduced cells and
cells transduced with a lentiviral vector expressing a doxycy-
cline-inducible control shRNA, and GB4 cells expressing a
doxycycline-inducible shRNA targeting c-Myc (GB4 c-myc KD)
were grown to approximately 50% conﬂuence in serum-free
media. They were then treated with either doxycycline
(10 ng/mL) alone or doxycycline (10 ng/mL) for 48 hours
before treatment with a single dose of 15 Gy and cell viability
determined.
GB4 tumor-bearing rats were treated 24 hours after imaging
with hyperpolarized [1-13C]pyruvate. Rats were anesthetized
using inhalation anesthetic and a lead collimator was used to
protect the snout and body. Animals were wrapped in insulating
plastic and silver foil tomaintain body temperature and Lubrithal
(Dechra) was applied for eye protection. For low-dose therapy,
temozolomide (100 mg/kg) was dissolved in 1 mL water and
administered by oral gavage 1 hour prior to radiotherapy. Radio-
therapy (15 Gy) was delivered over 825 seconds using a Cs-137
irradiator (IBL 637; CIS Bio International). The temozolomide
dose was split so that 50 mg/kg was given 1 hour prior to the ﬁrst
fraction of radiotherapy (15 Gy) and also 1 hour prior to the
second fraction (15 Gy) 72 hours later. A further 10 Gy radiation
dose was given 72 hours later giving a total of 40 Gy and 100
mg/kg of temozolomide.
Histopathology and IHC
Brains were excised and immediately placed in 10% forma-
lin (Sigma-Aldrich) for 24 hours, then in 70% ethanol and
then sectioned. Hematoxylin and eosin staining (H&E; ST020
Multistainer – Leica Microsystems) was performed on 5-mm
sections, which were cut using the surface injection site as a
guide for the center of the underlying tumor. Further 10-mm
sections were taken for TUNEL staining and IHC. TUNEL was
performed using Leica's Polymer Kit (Leica Microsystems) and
Promega's DeadEnd Colorimetric TUNEL System (Promega).
IHC was performed using Leica's Polymer Reﬁne Kit and
human-speciﬁc antibodies, speciﬁcally Ki67–1:200 dilution
(M7240, Dako), Monocarboxylate Transporter (MCT)
1–1:500 dilution (HPA003324, Atlas), MCT 4–1:500 dilution
(HPA021451, Atlas), Glial Fibrillary Acid Protein (GFAP)–
1:10,000 dilution (Z0334, Dako), c-Myc–1:50 dilution
(ab32072, Abcam), and pAKT–1:25 dilution (3787, Cell Sig-
naling Technology). Images were analyzed using Aperio
image-viewing software using in-house algorithms.
Mair et al.
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Western blotting
Protein was extracted from cell and tissue samples in Pierce
RIPA buffer, containing protease inhibitor and EDTA (Thermo
Fisher Scientiﬁc). Cell disruption was performed using either
sonication (cell culture; Bioruptor, Diagenode) or via homoge-
nization (tissues; Precellys, Bertin). Proteins were separated using
gel electrophoresis in NuPage Bis-Tris precast gels (Thermo
Fisher Scientiﬁc) and dry-blotted onto polyvinylidene diﬂuoride
(PVDF) membranes using an iBlot transfer stack (Thermo
Fisher Scientiﬁc). Subsequent analysis was performed using a
Odyssey Licor near-infrared digital ﬂuorescence imaging system
(LI-COR Biotechnology). Samples were analyzed in duplicate
or triplicate and data from technical replicates were averaged.
Antibodies were used at manufacturer recommended dilutions:
c-Myc–Abcam ab32072 1:10,000; pAKT Cell Signaling Techno-
logy #9271 1:1,000; HK2–Cell Signaling Technology #2106
1:1,000; LDHA–Cell Signaling Technology #3582 1:1,000.
Whole-exome sequencing
Massively parallel sequencing exome capture was perform-
ed using Illumina Nextera Rapid Capture, according to the
manufacturer's protocol. Fragment size was conﬁrmed using a
Bioanalyser (DNA1000 chip) before precapture pooling and
qPCR, using the KAPA Quantiﬁcation Kit, to conﬁrm DNA
concentration. Exome sequencing was performed on an Illu-
mina HiSeq 2500 using v4 chemistry generating 125-bp paired-
end reads with dual indexing. Variant calling used a pipeline
based on Burrows–Wheeler aligner (BWA). BWA-mem was used
for mapping sequencing reads to the human reference genome
(GRCh37; ref. 26). The genome analysis toolkit (GATK; version
3.5) was then used to apply local indel realignment and to
recalibrate base quality scores (27). Variant calling was carried
out jointly using the GATK HaplotypeCaller. Annotation of
variants was accomplished using ANNOVAR (28). Oncotator
was used for further annotation of candidate variants with
cancer relevant annotations (29).
Data availability
Raw data associated with the ﬁgures can be accessed at https://
doi.org/10.17863/CAM.26052.
Statistical analysis
All statistics were performed using GraphPad Prism (GraphPad
Software Inc) and MATLAB (MathWorks).
Results
Patient-derived orthotopic xenografts resemble the human
disease
Derivation of the cell lines and the conditions used to culture
them have been shown to give GB PDOX models that recapit-
ulate the biology of the tumors from which they were derived
(15, 16). The four models studied, originating from 4 individ-
ual patients with GB, showed variable growth rates and grew
more slowly than the U87 cell line model (Fig. 1A; ref. 30).
These models reproduced the morphology of the patient
tumors, for example, GB4 had a minimally inﬁltrative margin
compared with GB2, in both the patient tumor and correspond-
ing PDOX (Supplementary Fig. S1A). The models showed high
expression of a glial cell marker (GFAP; ref. 31) in vivo (Fig. 1B)
and a neural stem cell marker (nestin) in vitro (Fig. 1C; ref. 15).
U87 showed negligible expression of either marker. Exome
sequencing showed PTEN frameshift mutations in GB1–3
tumors, which resulted in protein loss (Supplementary Fig.
S1B), and in GB4 a frameshift (fs) mutation in PIK3R1 (V73fs),
which encodes the regulatory protein p85a and that could lead
to activation of PI3K (5, 32; Supplementary Table S1). Con-
sistent with these observations, all the models showed activa-
tion of the PI3K/Akt pathway, as indicated by phosphorylation
of Akt (pAkt; Supplementary Fig. S1C).
A patient-derived orthotopic xenograft showed increased
lactate labeling when compared with normal brain
13C images of non–tumor-bearing animals showed low inten-
sity signals from lactate (Fig. 1D). At 1 month after implantation
of GB4 cells, the hyperpolarized [1-13C]lactate/[1-13C]pyruvate
signal ratio (LPR) increased signiﬁcantly in the hemisphere con-
taining injected cells (Fig. 1E) compared with the contralateral
hemisphere (n ¼ 11, , P ¼ 0.02, paired t test; Fig. 1F). There was
no difference in noninjected controls (n ¼ 6, P ¼ 0.9, paired
t test; Fig. 1G). LPR was signiﬁcantly elevated in the right lower
brain quadrant, containing cells, when compared with the
left lower quadrant (Fig. 1H; n ¼ 11, , P ¼ 0.01, paired t test).
There was no difference in the upper right and left quadrants
(Fig. 1I). Because the cell injection needle passed through the
upper right quadrant, where there was no change in LPR, the
increased LPR in the lower right quadrant could not simply
be the result of tissue damage. At this stage, no tumor was visible
in T2-weighted
1H MR images of tissue water (Fig. 1J) and there
was no signal enhancement in T1-weighted images following
contrast agent injection (Fig. 1K and L).
Tumors derived from different patients showed variable
levels of lactate labeling
LPRs measured in tumor-containing regions, identiﬁed by
hyperintensity on T2-weighted
1H images, were signiﬁcantly
higher in GB3 and GB4 tumors, whereas GB1 and GB2 tumors
showed an LPR similar to normal brain (Fig. 2). Images were
acquired when tumors were approximately 0.1 cm3 or greater.
However, GB4 tumors were generally larger than GB1 tumors
(P¼ 0.03, GB4 n¼ 12, GB1 n¼ 5, unpaired t test; Supplementary
Fig. S1D) and therefore, to eliminate the potential confounding
effect of tumor size onLPR,we removed from the analysis all those
tumors above a threshold size of 0.35 cm3. When this was done,
there was no longer a signiﬁcant difference in volume between
GB1 and GB4 tumors (P¼ 0.3, GB4 n¼ 7, GB1 n¼ 6, unpaired t
test; Supplementary Fig. S1E) but the difference in LPR between
GB1 andGB4wasmaintained (P¼ 0.001, GB4: n¼ 7, GB1: n¼ 6,
unpaired t test; Supplementary Fig. S1F). The variability in label-
ing in the GB4 model, although large, is comparable with that
observed previously in U87 tumors in mice (33).
Lactate labeling correlated with c-Myc expression
Lactate labeling depends upon pyruvate delivery (34), lactate
concentration, and the activities of LDH (35) and the MCTs
(35, 36). Expression of the MCTs and enzymes in the glycolytic
pathway, including LDHA and HK2, is driven by c-Myc (10).
The concentrations of c-Myc, LDHA, and HK2 were higher in
GB3 and GB4 tumors, which showed high levels of lactate
labeling, than in GB1 and GB2 tumors (Fig. 3A–E). This trend,
however, was not repeated in cell culture, where GB3 cells
showed lower levels of c-Myc than GB2 but comparable levels
of LDHA and HK2 (Fig. 3F–H; Supplementary Fig. S2A–F). This
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does not appear to be due to hypoxia because none of the four
PDOX models shown here (GB1–GB4) expressed HIF1a in vivo
(Supplementary Fig. S2G), and only one (GB5), out of the 5
PDOXs studied, expressed HIF1a in vivo (Supplementary Fig.
S2G). None of the cell lines expressed HIF1a in culture
(Supplementary Fig. S2H). Localized proton spectroscopy
measurements gave GB4 tumor lactate concentrations of 2 to
8 mmol/L (n ¼ 4), as compared with 2 mmol/L in normal rat
cortex (n ¼ 2), consistent with an association between
increased HK2 levels and aerobic glycolysis in GB (32). Proton
spectra of the brains of two of the four GB4 tumor-bearing
animals and spectra from the brains of the two non–tumor-
bearing animals are shown in Supplementary Fig. S3. Increased
plasma membrane expression of MCTs, a negative prognostic
factor in the clinic (37), was observed in tumors with a high
LPR (MCT1 in GB3 and GB4 and MCT4 in GB4; Fig. 3I).
Expression of c-Myc (38) and HK2 (39) have been associ-
ated with a worse prognosis. We observed a positive correla-
tion between c-Myc expression and LPR (n ¼ 2 per GB cohort,
r2 ¼ 0.83, , P ¼ 0.0017, linear regression; Fig. 3J), and a
correlation, although poorer, between growth rate (Fig. 1A)
and c-Myc expression (Fig. 3A, D, and E), with GB1 tumors
showing comparable growth rates with GB3 tumors and only
slightly lower growth rates than GB4 tumors. However, there
was no correlation between tumor growth rate and cell pro-
liferation, as assessed by Ki67 staining, with slower growing
GB1 tumors, with low c-Myc expression, showing signiﬁcantly
(P < 0.0001) higher levels of Ki67 staining (Supplementary
Fig. S2I) than faster growing GB4 tumors, with high c-Myc
expression. The reasons for this discrepancy between tumor
cell proliferation and tumor growth rate are unclear but cannot
be explained by higher rates of cell turnover in GB1 tumors
Figure 1.
PDOXs resemble human GB and show increased LPR when compared with normal brain tissue. A, Time taken from cell implantation for tumors to
reach >0.05 cm3 (GB1, n ¼ 9; GB2, n ¼ 7; GB3, n ¼ 5; GB4, n ¼ 21; U87, n ¼ 14; P < 0.0001). All of the cell lines showed high levels of tumor initiation
and growth following orthotopic cell implantation (GB1, 9 tumors from 9 implantations; GB2, 9/9; GB3, 5/6; GB4, 23/25). B, Percentage of cells showing
immunostaining for GFAP in the PDOX and U87 tumor models (GB1, n ¼ 7; GB2, n ¼ 5; GB3, n ¼ 2; GB4, n ¼ 19; U87, n ¼ 8). C, Western blot analysis
of nestin expression in the indicated cell lines in vitro. D and E, Representative false color images of the LPR superimposed on a T2-weighted
1H image
(grayscale) of a control brain (no implanted tumor cells; D) and a brain one month after implantation of GB4 cells (arrow, site of implantation; E). Scale bar,
LPR. Representative T2-weighted image (J) and T1-weighted
1H images before (K) and after (l) contrast agent injection and one month after GB4 cell
implantation (arrow, the site of implantation). F, LPRs averaged over the hemispheres containing implanted cells (right) and nonimplanted (left) one month
after GB4 cell implantation. The ratio was signiﬁcantly higher in the right hemisphere ( , P¼ 0.02, n¼ 11, paired t test). G, LPRs in control brains, which showed
no signiﬁcant difference between the hemispheres (P ¼ 0.9, n ¼ 6, paired t test). LPRs averaged over the lower (H) and upper (I) quadrants of the indicated
hemispheres one month after GB4 cell implantation in the bottom right brain quadrant. There was a signiﬁcant increase in the quadrant containing implanted
cells (right;  , P ¼ 0.01, n ¼ 11, paired t test) but no signiﬁcant difference between the top quadrants (P ¼ 0.3, n ¼ 11, paired t test).
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because there was no difference in the levels of cell death
(TUNEL staining) between untreated GB1 and GB4 tumors
(Supplementary Fig. S2J).
Inhibition of the PI3K/Akt pathway has been shown previ-
ously to decrease GB lactate labeling in animal models injected
with hyperpolarized [1-13C]pyruvate (14). However, here there
was a negative correlation between the levels of pAKT and
LPR (n ¼ 2 per GB cohort, r2 ¼ 0.76, P ¼ 0.0047; Fig. 3K).
We conﬁrmed that c-Myc–driven expression of LDHA and
HK2 was responsible for increased lactate labeling by knocking
down c-Myc expression in GB4 cells. Doxycycline treatment
of GB4 cells expressing a doxycycline-inducible shRNA target-
ing c-Myc (GB4 c-Myc KD) substantially decreased c-Myc,
LDHA, and HK2 expression (Fig. 4A–C), and in tumors derived
from these cells, LPR was decreased 7 days after addition of
doxycycline to the diet of tumor-bearing animals (Fig. 4D–F).
Variable lactate labeling in the tumor models reﬂects intra
and intertumoral heterogeneity in patients with GB
Lactate labeling and c-Myc, LDHA, HK2, and MCT expression
were reproducible between PDOXs derived from the same patient
but different to those derived from other patients. To determine
whether this was due to inter or intratumoral heterogeneity, we
conducted 5ALA ﬂuorescence-guided multiregion tumor sam-
pling (40) in 4 patients with GB. The levels of c-Myc, HK2, and
LDHA varied between 3 to 5 spatially disparate samples (Sup-
plementary Fig. S4A–G), indicating that PDOX heterogeneity
reﬂects patient intra- as well as intertumoral heterogeneity. As in
thePDOXmodels, LDHAandHK2expressionwas correlatedwith
c-Myc expression (Supplementary Fig. S4H and S4I; 3–5 regions/
tumor, 2 technical replicates per location, r2¼0.30,P¼0.036 and
r2 ¼ 0.27, P ¼ 0.048, respectively).
Inhibition of c-Myc expression increased radiosensitivity in
cultured cells
Expression of HK2 and LDHA have been negatively corre-
lated with radiosensitivity (39, 41), suggesting that metabolic
imaging with hyperpolarized [1-13C]pyruvate could be used to
target increased radiotherapy dose to areas of radioresistance.
We investigated this by comparing the effects of irradiation
on GB4 and GB1 cells. Following irradiation, GB4 cells, which
have a high LPR in vivo (Fig. 2F) and high c-Myc expression
in vitro and in vivo (Fig. 3A and D), showed a greater preser-
vation of viability than GB1 cells (Fig. 4G, P < 0.0001),
which have a lower LPR in vivo (Fig. 2F) and lower levels of
c-Myc in vitro and in vivo (Fig. 3A and D). Doxycycline-induced
c-Myc knockdown in GB4 cells resulted in a greater decrease
in cell viability following irradiation (Fig. 4H). Control cells
(nontransduced cells or cells transduced with a control shRNA)
showed no signiﬁcant difference in viability following irradi-
ation in the presence or absence of doxycycline (Supplement-
ary Fig. S5).
Radiotherapy results in decreased lactate labeling in GB4
tumors
GB4 tumors responded to radiotherapy and temozolomide
treatment with a decrease in LPR 72 hours after treatment (P ¼
0.038, n ¼ 6, paired t test; Fig. 4I–K). TUNEL staining of excised
tumor sections showed that this was accompanied by signiﬁcant
increases in cell death (P¼0.0089, n¼11untreated, n¼8 treated,
unpaired t test; Fig. 4L).
Discussion
Studies in human brain tumors and in patient-derived GB
xenografts implanted orthotopically in immunocompromised
mice have shown that contrary to expectations, where the
tumors were expected to be predominantly glycolytic, there
was extensive oxidation of glucose in the tricarboxylic acid
(TCA) cycle (42, 43). In these experiments, the patients and
mice were infused with 13C-labeled glucose immediately prior
to tumor resection and the 13C-labeling patterns in tumor
metabolites were analyzed by 13C NMR measurements on
tumor extracts. The relatively low levels of lactate labeling
Figure 2.
The different tumor models showed differences in hyperpolarized [1-13C]lactate/[1-13C]pyruvate signal ratios. Representative false color images of the
LPR superimposed on T2-weighted
1H images (grayscale) from animals implanted with GB1 cells (A), GB2 cells (B), GB3 cells (C), GB4 cells (D), and
U87 cells (E). Spectra from representative voxels are also shown. F, LPRs in tumors resulting from implantation of the indicated cell lines. Controls were
not implanted with cells. ( , P < 0.009;  , P < 0.0004;  , P < 0.0001; control, n ¼ 6; GB1, n ¼ 5; GB2, n ¼ 9; GB3, n ¼ 3; GB4, n ¼ 12; U87, n ¼ 10;
unpaired t test). Images were acquired at the following times after cell implantation: GB1, 153 days; GB2, 322 days; GB3, 163 days; GB4, 121 days; U87, 27 days.
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Figure 3.
Expression of c-Myc, LDHA, and HK2 and MCT plasma membrane localization are correlated with the LPR. A-C, Western blot analysis of the expression of
c-Myc (A), LDHA (B), and HK2 (C) in the indicated tumor models. D and E, IHC staining of c-Myc in the indicated tumor models (D) and quantitative analysis (E)
of these data ( , P ¼ 0.009, n ¼ 2–5, unpaired t test). Expression of c-Myc (F), LDHA (G), and HK2 (H) in the corresponding cell lines cultured in vitro
( , P < 0.05;  , P < 0.007;  , P < 0.0005, unpaired t test). For c-Myc, there were three biological replicates and for LDHA and HK2, two and two technical
replicates for each sample. Band intensities were normalized to that for b-actin. I, IHC analysis of MCT1 and MCT4 expression in the indicated tumor
models; plasma membrane localization is evident in GB3 and GB4 tumors. J and K, Correlations between LPRs measured in vivo and c-Myc expression
(r2 ¼ 0.83; , P ¼ 0.002, n ¼ 4, linear regression; J) and phosphorylated Akt (pAKT; r2 ¼ 0.76;  , P ¼ 0.005, n ¼ 4, linear regression; K), determined by
Western blotting, in the indicated tumor models.
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observed in the PDOX models used here, which were
similar to those observed in normal brain, are consistent
with these previous studies. The much higher levels of
lactate labeling observed in the established cell line model
used here (U87), and in the GB cell line models used in
previous studies with hyperpolarized [1-13C]pyruvate (14),
which have been shown to be poor models of human brain
tumors (15), reﬂect presumably their extended lifetime in
culture and their very high rates of proliferation rather than
being a necessary feature of malignancy. Previous studies
with hyperpolarized [1-13C]pyruvate in these cell line mod-
els of glioma may, therefore, be overestimating the levels of
labeled lactate that are likely to be observed in the clinic.
The PDOX models used here, which showed much higher
levels of expression of glial (GFAP) and neural stem cell
(nestin) markers than the U87 model, are better represen-
tative of the human disease.
The patterns of lactate labeling were reproducible between
GB PDOXs derived from the same patient but different to
those derived from other patients. Multiregion sampling of
individual patients with GB showed this likely reﬂected inter
and intratumoral heterogeneity (40). The relatively low
levels of lactate labeling in the PDOXs have important
implications for translation of this technique to the clinic
because they suggest that some tumors, or some regions of
tumors, may show lactate labeling that is indistinguishable
from labeling in normal brain. However, the observation of
increased lactate labeling in brain regions where no tumor
was apparent in a T2-weighted
1H image of tissue morphol-
ogy also suggests that the technique has the potential to
Figure 4.
Inhibition of c-Myc expression decreased the LPR and increased radiosensitivity. A-C, Expression of c-Myc, LDHA, and HK2 (normalized to b-actin) 48 hours
after addition of doxycycline (dox) to GB4 c-Myc KD cells. There were two biological replicates and two technical replicates per sample (, P < 0.05,
unpaired t test). D, Change in the LPRs in tumors resulting from orthotopic implantation of GB4 c-Myc KD and GB4 cells one week after addition of
doxycycline to the diet ( , P ¼ 0.035, n ¼ 3, paired t test). LPR images, superimposed on grayscale 1H images, of a GB4 c-Myc KD tumor-bearing rat
before (E) and after (F) addition of doxycycline to the diet. G, Response of GB4 and GB1 cells to 15 Gy radiation at day 0 (P < 0.0001; two biological replicates;
50 technical replicates; unpaired t test). Viability is shown as the percentage of viable cells determined using an automated Trypan blue dye exclusion
assay, as described in the Materials and Methods. H, GB4 c-Myc KD cells cultured with doxycycline for 48 hours prior to radiation with 15 Gy
showed a signiﬁcant increase in the loss of cell viability (P ¼ 0.008; four biological replicates; 50 technical replicates; unpaired t test). There was no
signiﬁcant difference in the change in viability following irradiation of GB4 cells and GB4 cells expressing a control shRNA between those cells that
had previously been incubated with doxycycline and those that had not (Supplementary Fig. S5). LPR images superimposed on 1H images of a GB4 tumor
before (I) and after (J) treatment with temozolomide and 40 Gy of radiation. K, LPRs at 72 hours after treatment with temozolomide and 40 Gy of radiation ( ,
P ¼ 0.038, n ¼ 6, paired t test). l, TUNEL staining of untreated tumors and tumors 72 hours after treatment with temozolomide and 40 Gy of radiation ( , P <
0.0089; n ¼ 11 untreated; n ¼ 8 treated; unpaired t test).
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improve tumor detection, at least in those tumors with
higher levels of lactate labeling. A similar observation was
made in a clinical study in the prostate, where lactate
labeling was observed in tumor tissue that was not detect-
able in a T2-weighted
1H image (13).
Although lactate labeling levels were relatively low, we
nevertheless observed consistent differences between the dif-
ferent models, which could not be explained by differences in
PI3K/Akt pathway activity but which were correlated with the
levels of c-Myc, LDHA, HK2, and plasma membrane locali-
zation of MCT1 and MCT4. The role of c-Myc in determining
tumor lactate labeling, by driving increased expression of
HK2 and LDHA, was conﬁrmed by knocking down c-Myc
expression in GB4 tumors. This reduced the expression of
LDHA and HK2 and decreased lactate labeling. The levels of
c-Myc in GB appear to be upregulated by two complemen-
tary mechanisms: alternative splicing of deltaMax (44) and
mTORC2-dependent phosphorylation and inhibition of
HDACs, leading to acetylation and inactivation of FoxO and
relief of mir-34c–dependent c-Myc suppression (38). In this
latter study, treatment of GB cells with PI3K or Akt inhibitors
was shown to elevate c-Myc levels and increase the levels of
LDHA and HK2. Consistent with these observations we
observed a negative correlation between the levels of pAkt
and lactate labeling. The patterns of c-Myc, HK2, and LDHA
expression observed in the tumors in vivo were not entirely
reproduced in the cells cultured in vitro. This effect of the
tumor microenvironment on gene expression is consistent
with a recent RNAi screen of epigenetic modiﬁers in GB
(45), which showed very different results when cells were
grown in culture or as orthotopic xenografts.
The expressions of c-Myc (8, 9) and plasma membrane
localization of MCT1 and MCT4 (37) have been shown pre-
viously to correlate with tumor grade, increased HK2 expres-
sion has been correlated with worse overall survival (39),
and 1H MRS measurements have demonstrated higher lactate
concentrations in grade 3 and 4 tumors (46). Therefore, 13C
MRSI measurements of GB lactate labeling could provide
prognostic information in the clinic. Moreover, because ther-
apeutic resistance to PI3K or Akt inhibition is mediated by
sustained c-Myc activity (38), the technique should also be
capable of early detection of drug resistance and response
to drugs that modulate c-Myc expression (38, 47). The tech-
nique could potentially be used to select patients for metabolic
therapies, for example, drugs that target increased c-Myc–
driven glycolysis, such as the nicotinamide phosphoribosyl-
transferase inhibitor, which has demonstrated efﬁcacy in c-
Myc–driven GB cells and in patient-derived orthotopic GB
xenografts (48).
Detection of response to radiotherapy has been shown previ-
ously in a rat cell line gliomamodel (C6; ref. 25), where response
was evident as a decrease in lactate labeling. We have demon-
stratedhere inGB4 tumors,which likeC6 tumors showhigh levels
of lactate labeling, that response to concomitant temozolomide
and radiation treatment results in decrease in lactate labeling,
which was explained by increased levels of cell death. However,
detection of response using this technique in those tumors that
show much lower levels of lactate labeling may be challenging
as the decrease in lactate labeling posttreatment would neces-
sarily be less.
Inhibition of LDHA (41) or HK2 (39) has been shown to
sensitize GB cells to radiotherapy and we have shown that c-Myc
and glycolytic enzyme expression are correlated with the radio-
resistance of the cell lines in vitro. Therefore, imaging with hyper-
polarized [1-13C]pyruvate could potentially be used clinically to
target increased radiotherapy dose to radioresistant tumors or
speciﬁc regions of tumors, that is, regions that display increased
lactate labeling. PET with 11C methionine, where the resolution
was 4.8 mm, has been used to target radiotherapy in patients
with GB (49). Because the resolution in the ﬁrst clinical studies
with hyperpolarized [1-13C]pyruvate in prostate was between 7
and 15 mm (13), the technique may have sufﬁcient spatial
resolution to do this.
In summary, increased levels of lactate labeling in GB PDOX
models can be explained by increased levels of LDHA, HK2, and
plasma membrane MCTs resulting from increased c-Myc expres-
sion. With the recent translation of this technique to the clinic,
metabolic imaging with hyperpolarized [1-13C]pyruvate could be
used clinically for determining disease prognosis, for assessing
response to drugs that are effective in reducing the levels of c-Myc,
inducing cell death, and for targeting radiation at tumor regions
with high c-Myc expression and which are expected to be
radioresistant.
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